ceffect 25 mg/ml suspension for injection for cattle and pigs
emdoka - cefquinome sulphate - suspension for injection - 25 milligram(s)/millilitre - cefquinome - cattle, pigs - antibacterial
ceffect lc, 75 mg, intramammary ointment for lactating cows
emdoka bvba - cefquinome sulphate - intramammary ointment - 75 mg/syringe - cefquinome - cattle - antibacterial
ceffect 25 mg/ml suspension for injection for cattle and pigs
emdoka bvba - cefquinome (as sulfate) - suspension for injection - 25 mg/ml - cefquinome - bovine, porcine - antibacterial
ceffect lc, 75 mg, intramammary ointment for lactating cows
emdoka bvba - cefquinome (as sulfate) - intramammary ointment - 75 milligram - cefquinome - bovine - antibacterial
ceffect 25 mg/ml suspension for injection for cattle and pigs
emdoka bvba - cefquinome - suspension for injection - antimicrobial - cattle, pigs
ceffect lc, 75 mg, intramammary ointment for lactating cows
emdoka bvba - cefquinome - intramammary ointment - antimicrobial intramammary - cattle
ceffect 25 mg/ml inj. susp. i.m. vial
emdoka s.p.r.l.-b.v.b.a. - cefquinome sulfate 29,64 mg/ml - eq. cefquinome 25 mg/ml - suspension for injection - 25 mg/ml - cefquinome sulfate 29.64 mg/ml - cefquinome - cattle; pig
ceffect lc 75 mg i.mamm. ointm. syr.
emdoka s.p.r.l.-b.v.b.a. - cefquinome sulfate 11,115 mg/g - eq. cefquinome 9,375 mg/g - intramammary ointment - 75 mg - cefquinome sulfate 11.115 mg/g - cefquinome - cattle
otrivin
novartis consumer health s.a. - xylometazoline (xylometazoline hydrochloride) - drops nasal - 0,5mg/ml
nitrofurantoin- nitrofurantoin macrocrystals capsule
bryant ranch prepack - nitrofurantoin (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - nitrofurantoin macrocrystals capsules are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of escherichia coli , enterococci, staphylococcus aureus , and certain susceptible strains of klebsiella and enterobacter species. nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin macrocrystals capsules and other antibacterial drugs, nitrofurantoin macrocrystals capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader tissue distribution of other therapeut